MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)
Conditions: Malignant Neoplasms of Urinary Tract; Other Disorders of Kidney and Ureter; Renal Cell Carcinoma Interventions: Drug: MGCD516; Drug: Nivolumab Sponsors: M.D. Anderson Cancer Center; Mirati Therapeutics Inc. Not yet recruiting - verified January 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Ureter and Renal Pelvis Cancer | Urology & Nephrology